ClinicalTrials.gg
CompletedNCT02572167Updated Nov 8, 2022Results posted

A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

A Phase 1/2 interventional study of brentuximab vedotin and nivolumab in Hodgkin Lymphoma, sponsored by Seagen Inc.. Completed at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-08.

Sponsored by Seagen Inc. (part of Pfizer) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
93
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies testing Brentuximab Vedotin in Hodgkin Disease — 14 open to participants now, 28 under way, 8 of them phase 3. Brentuximab Vedotin · Hodgkin Disease.

Enrollment
21st of 80
93 · median 52
Started
2015
with 8 others
Phase 1/2
12 of 80
none open now
Registered
44th of 80
by date
Lead sponsor
12 of 80
Seagen Inc.

Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, this one is the 21st largest by enrollment, is one of 9 that started in 2015, is one of 12 in phase 1/2, and was the 44th registered.

Hodgkin Disease

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

14 of the 80 studies testing Brentuximab Vedotin in Hodgkin Disease are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Brentuximab Vedotin

Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies testing Brentuximab Vedotin in Hodgkin Disease, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety profile and antitumor activity of brentuximab vedotin administered in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma (HL)

Read the detailed description

This study will examine the safety profile and antitumor activity when brentuximab vedotin is combined with nivolumab. Patients will be treated for up to four 21-day cycles with brentuximab vedotin 1.8 mg/kg and nivolumab 3 mg/kg.

There will be 3 parts to this study. In Part 1, the safety of combination treatment will be evaluated by a Safety Monitoring Committee (SMC) prior to expansion of enrollment to evaluate treatment effect in Part 2. Part 2 of the study will further characterize the safety and antitumor activity of brentuximab vedotin combined with nivolumab by enrolling patients at the recommended dose schedule determined in Part 1. Part 3 of the study will evaluate the safety and antitumor activity of combination treatment administered at an alternate dosing schedule determined by cumulative safety and activity data from Parts 1 and 2.

03

Conditions studied

  • Hodgkin Lymphoma

Browse trials for

Keywords

  • Monomethyl auristatin E
  • Antigens, CD30
  • Antibody-Drug Conjugate
  • Antibodies, Monoclonal
  • Immunotherapy
  • Autologous stem cell transplant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hodgkin lymphoma following failure of standard frontline chemotherapy for the treatment of classical Hodgkin lymphoma
  • (ECOG) performance status of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Previously treated with brentuximab vedotin, immune-oncology agents, or received an or autologous stem cell transplant
  • Documented history of a cerebral vascular event
  • History of another invasive that has not been in remission for at least 3 years
  • History of progressive multifocal leukoencephalopathy (PML)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
93 participants (actual)

Study arms

  • Experimental
    Brentuximab Vedotin + Nivolumab

    Brentuximab vedotin plus nivolumab

    Drug: brentuximab vedotin · Drug: nivolumab

Interventions

  • 1.8 mg/kg by intravenous (IV) infusion for up to 4 cycles

    Also known as: SGN-35, ADCETRIS

  • 3 mg/kg by intravenous (IV) infusion for up to 4 cycles

    Also known as: BMS-936558, OPDIVO

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    Treatment-emergent adverse events (TEAEs) are presented and defined as newly occurring (not present at baseline) or worsening after first dose of investigational product. The timeframe includes a 6.01 month safety reporting period and additional long-term follow up through 28.9 months.

    Time frame: Up to 28.9 months

  2. Complete Remission Rate

    Number of patients with complete metabolic response (CMR) at end of treatment

    Time frame: Up to 3.42 months

Secondary outcomes

  1. Objective Response Rate

    Number of patients with complete metabolic response (CMR) or partial metabolic response (PMR)

    Time frame: Up to 3.42 months

  2. Duration of Complete Response

    The time from start of the first documentation of complete response (CR) to the first documentation of tumor progression (PD) including radiographic evidence of progression and clinical progression per investigator or to death due to any cause, whichever comes first.

    Time frame: Up to 69.3 months

  3. Duration of Objective Response

    The time from start of the first documentation of OR (CR or PR) to the first documentation of PD or to death due to any cause, whichever comes first.

    Time frame: Up to 69.3 months

  4. Progression-free Survival Post-autologous Stem Cell Transplant

    For participants who undergo ASCT, the time from ASCT to the first documentation of PD or to death due to any cause, whichever comes first.

    Time frame: Up to 67.3 months

07

Results

Posted Mar 7, 2019

Participant flow

Participant flow — Overall Study
MilestonePart 1: Staggered DosePart 2: Staggered Dose ExpansionPart 3: Same-day Dose
Started65631
Completed000
Not completed65631
Withdrew: Withdrawal by subject030
Withdrew: Lost to follow-up253
Withdrew: Death083
Withdrew: Did not meet inclusion criteria001
Withdrew: Study closure by sponsor44024

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs)

Treatment-emergent adverse events (TEAEs) are presented and defined as newly occurring (not present at baseline) or worsening after first dose of investigational product. The timeframe includes a 6.01 month safety reporting period and additional long-term follow up through 28.9 months.

Time frame:
Up to 28.9 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsPart 1: Staggered DosePart 2: Staggered Dose ExpansionPart 3: Same-day Dose
Any treatment-emergent adverse event (TEAE)65530
AEs related to brentuximab vedotin only54115
AEs related to nivolumab only32013
AEs related to both study drugs53727
Any serious adverse event (SAE)0165
SAEs related to brentuximab vedotin only020
SAE related to nivolumab only040
SAE related to both study drugs054
AEs leading to treatment discontinuation011
PrimaryComplete Remission Rate

Number of patients with complete metabolic response (CMR) at end of treatment

Time frame:
Up to 3.42 months
Reported as:
Count of participants · Participants
Complete Remission Rate
ParticipantsPart 1: Staggered DosePart 2: Staggered Dose ExpansionPart 3: Same-day Dose
Complete Remission Rate43324
SecondaryObjective Response Rate

Number of patients with complete metabolic response (CMR) or partial metabolic response (PMR)

Time frame:
Up to 3.42 months
Reported as:
Count of participants · Participants
Objective Response Rate
ParticipantsPart 1: Staggered DosePart 2: Staggered Dose ExpansionPart 3: Same-day Dose
Objective Response Rate64328
SecondaryDuration of Complete Response

The time from start of the first documentation of complete response (CR) to the first documentation of tumor progression (PD) including radiographic evidence of progression and clinical progression per investigator or to death due to any cause, whichever comes first.

Time frame:
Up to 69.3 months
Reported as:
Median · Months
Duration of Complete Response
MonthsPart 1: Staggered DosePart 2: Staggered Dose ExpansionPart 3: Same-day Dose
Duration of Complete ResponseNA (0 to 69.3)NA (0 to 61.9)NA (0 to 50.4)
SecondaryDuration of Objective Response

The time from start of the first documentation of OR (CR or PR) to the first documentation of PD or to death due to any cause, whichever comes first.

Time frame:
Up to 69.3 months
Reported as:
Median · Months
Duration of Objective Response
MonthsPart 1: Staggered DosePart 2: Staggered Dose ExpansionPart 3: Same-day Dose
Duration of Objective ResponseNA (0 to 69.3)NA (0 to 61.9)NA (0 to 50.4)
SecondaryProgression-free Survival Post-autologous Stem Cell Transplant

For participants who undergo ASCT, the time from ASCT to the first documentation of PD or to death due to any cause, whichever comes first.

Time frame:
Up to 67.3 months
Reported as:
Median · Months
Progression-free Survival Post-autologous Stem Cell Transplant
MonthsPart 1: Staggered DosePart 2: Staggered Dose ExpansionPart 3: Same-Day Dose
Progression-free Survival Post-autologous Stem Cell TransplantNA (0 to 67.3)NA (0 to 61.1)NA (0 to 48.8)

Adverse events

Collected over Non-serious adverse events were followed up to 6.01 months. Serious adverse events and all-cause mortality were followed up to 72 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Staggered Dose0/6 (0%)0/6 (0%)6/6 (100%)
Part 2: Staggered Dose Expansion8/56 (14.3%)16/55 (29.1%)55/55 (100%)
Part 3: Same-day Dose3/31 (9.7%)5/30 (16.7%)30/30 (100%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventPart 1: Staggered DosePart 2: Staggered Dose ExpansionPart 3: Same-day Dose
PneumonitisRespiratory, thoracic and mediastinal disorders0/64/552/30
PneumoniaInfections and infestations0/63/551/30
PyrexiaGeneral disorders0/63/551/30
NauseaGastrointestinal disorders0/62/550/30
Febrile neutropeniaBlood and lymphatic system disorders0/62/550/30
Respiratory failureRespiratory, thoracic and mediastinal disorders0/61/551/30
SepsisInfections and infestations0/61/551/30
CellulitisInfections and infestations0/60/551/30
Necrotising soft tissue infectionInfections and infestations0/60/551/30
Septic shockInfections and infestations0/60/551/30
Most frequent other events
Showing 10 of 153
Most frequent other events
EventPart 1: Staggered DosePart 2: Staggered Dose ExpansionPart 3: Same-day Dose
FatigueGeneral disorders6/639/5528/30
NauseaGastrointestinal disorders6/641/5528/30
VomitingGastrointestinal disorders6/625/5518/30
ThrombocytopeniaBlood and lymphatic system disorders6/629/5520/30
AnaemiaBlood and lymphatic system disorders6/624/5516/30
NeutropeniaBlood and lymphatic system disorders6/619/5512/30
PruritusSkin and subcutaneous tissue disorders5/630/5515/30
DiarrhoeaGastrointestinal disorders5/632/5522/30
Febrile neutropeniaBlood and lymphatic system disorders5/612/556/30
StomatitisGastrointestinal disorders4/619/5512/30

Baseline characteristics

All Treated Subjects analysis set includes all subjects who received any amount of brentuximab vedotin or nivolumab.

Age, Continuous
Age, Continuous(years)Part 1: Staggered DosePart 2: Staggered Dose ExpansionPart 3: Same-day DoseTotal
Median26.0 (20 to 37)37.0 (18 to 69)31.5 (20 to 66)34.0 (18 to 69)
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Staggered DosePart 2: Staggered Dose ExpansionPart 3: Same-day DoseTotal
Female5271951
Male1281140
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Staggered DosePart 2: Staggered Dose ExpansionPart 3: Same-day DoseTotal
Hispanic or Latino14914
Not Hispanic or Latino5492074
Unknown or Not Reported0213
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Staggered DosePart 2: Staggered Dose ExpansionPart 3: Same-day DoseTotal
American Indian or Alaska Native0011
Asian0325
Native Hawaiian or Other Pacific Islander0000
Black or African American0202
White6472477
More than one race0224
Unknown or Not Reported0112
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Part 1: Staggered DosePart 2: Staggered Dose ExpansionPart 3: Same-day DoseTotal
Grade 04351958
Grade 12201032
Unknown0011
08

Study locations

13 sites
  • City of Hope National Medical Center
    Duarte, California 91010-3000, United States
  • Stanford Cancer Center
    Stanford, California 94305, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Karmanos Cancer Institute / Wayne State University
    Detroit, Michigan 48201, United States
  • Mayo Clinic Minnesota
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198-7680, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Memorial Sloan Kettering Cancer Center - Commack
    Commack, New York 11725, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10021, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • James Cancer Hospital / Ohio State University
    Columbus, Ohio 43210, United States
  • Charles A. Sammons Cancer Center / Baylor University Medical Center
    Dallas, Texas 75246, United States
09

References and documents

Publications

  • Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Ansell SM, Moskowitz CH, Fenton K, Ogden CA, Taft D, Zhang Q, Kato K, Campbell M, Advani RH. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018 Mar 15;131(11):1183-1194. doi: 10.1182/blood-2017-10-811224. Epub 2017 Dec 11. PubMed 29229594 ↗
  • Advani RH, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Christian BA, Ansell SM, Moskowitz CH, Brown L, Zhang C, Taft D, Ansari S, Sacchi M, Ho L, Herrera AF. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood. 2021 Aug 12;138(6):427-438. doi: 10.1182/blood.2020009178. PubMed 33827139 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Mar 2018, 28 months.

Results were first posted in Mar 2019, 1 year after primary completion.

Of 63 phase 1/2 interventional studies under Hodgkin Disease, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 53 and three quarters within 97. This study's 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2015
First posted
Oct 8, 2015
StartActual
Oct 31, 2015
Primary completionActual
Mar 1, 2018
CompletionActual
Oct 21, 2021
Results first posted
Mar 7, 2019
Last update
Nov 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02572167
Lead sponsor
Seagen Inc.
Responsible party
Sponsor
First posted
Oct 8, 2015
Start date
Oct 31, 2015
Primary completion
Mar 1, 2018
Completion
Oct 21, 2021
Results posted
Mar 7, 2019
Last update
Nov 8, 2022

Study contacts

Faith Galderisi, DO
study director · Seagen Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Brentuximab Vedotin · Nivolumab

Start the discussion